Menu
Wugen Ramps Up Off-the-Shelf Gene Therapies to Fight Cancer
Biospace, Kate Goodwin, January 2021
Read More
ARCHIVE
ARCHIVE
Wugen
Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia
Cancer Discovery, Berrien-Elliott et al, December 2020
Read MoreWugen Appoints New Vice President and Head of NK Research as the Company Continues to Expand its Pipeline
ST. LOUIS, Nov. 19, 2020 /PRNewswire/ -- Wugen Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced the appointment of Ryan Sullivan, Ph.D., as Vice President and Head of…
Read MoreCAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas
Blood, Gang et al, November 2020
Read MoreMemory-like natural killer cells for cancer immunotherapy
Seminars in Hematology, Gang et al, November 2020
Read MoreChimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies
Best Practice & Research Clinical Haematology, Cooper and DiPersio, December 2019
Read MoreWugen Adds to Leadership Team as Company Continues to Lay Groundwork for Future Expansion
ST. LOUIS, April 30, 2019 /PRNewswire/ -- Wugen Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced the appointment of Mark Lewis, Ph.D., as Vice President of Finance…
Read MoreWUGEN Expands Leadership Team with Appointment of a Vice President of Research and Development and a Vice President of Product Development
ST. LOUIS, March 26, 2019 /PRNewswire/ -- WUGEN Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced the appointment of Ayman Kabakibi, Ph.D., as Vice President of Research and…
Read MoreWUGEN Presents New Data for Key CAR-T Platform at the 2019 Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR
ST. LOUIS, Feb. 20, 2019 /PRNewswire/ -- WUGEN Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced data presentations at the 2019 Transplantation & Cellular Therapy (TCT) Meetings…
Read MoreWUGEN Presents Updated Preclinical Data on Novel Allogeneic CAR-T Platform at ASH Annual Meeting
ST. LOUIS, Dec. 3, 2018 /PRNewswire/ -- WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced updated preclinical data that validates its off-the-shelf fratricide-resistant CAR-T platform.…
Read More
Copyright © 2024 Wugen. All Rights Reserved.
a COGNEO design